Increased serum levels of advanced glycation end-products is associated with severity of sleep disordered breathing but not insulin sensitivity in non-diabetic men with obstructive sleep apnoea

Sleep Medicine

Volumn 13, Issue 1, 2012, Pages 15-20

  Lam, Jamie C M ^a   Tan, Kathryn C B ^a   Lai, Agnes Y K ^a   Lam, David C L ^a   Ip, Mary S M ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Advanced glycation end products; CPAP treatment; Insulin sensitivity; Non diabetic men; Obstructive sleep apnoea; Severity of sleep disordered breathing

Indexed keywords

ADVANCED GLYCATION END PRODUCT; GLUCOSE;

ADULT; AGED; APNEA HYPOPNEA INDEX; ARTICLE; BLOOD LEVEL; BODY MASS; CHINESE; COMORBIDITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; HONG KONG; HUMAN; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; POLYSOMNOGRAPHY; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; SLEEP APNEA SYNDROME;

EID: 84355161923     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2011.07.015     Document Type: Article

References (46)

1. Thornalley P.J., Battah S., Ahmd N., Karachalias N., Agalou S., Babaei-Jadidi R., et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003, 375:581-592.
2. Schmidt A.M., Yan S.D., Wautier J.L., Stern D. Activation of receptor for advanced glycation endproducts: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999, 84:489-497.
3. Singh R., Barden A., Mori T., Beilin L. Advanced glycation end-products: a review. Diabetologia 2001, 44:129-146.
4. Ahmed N., Thornalley P.J. Advanced glycation endproducts: what is their relevance to diabetic complications. Diabetes Obes Metab 2007, 9:233-245.
5. Vlassara H., Uribarri J. Glycoxidation and diabetic complications: modern lessons and a warning?. Rev Endocrinol Metab Disord 2004, 5:181-188.
6. Friedman E.A. Advanced glycosyation end-products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care 1999, 22(Suppl. 2):B65-B71.
7. Feng L., Matsumoto C., Schwartz A., Schmidt A.M., Stern D.M., Pile-Spellman J. Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis. Diabetes Care 2005, 28:379-384.
8. Stehouwer C.D.A., Gall M.A., Twisk J.W.R., Knudsen E., Emeis J.J., Parving H.H. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes. Diabetes 2002, 51:1157-1165.
9. Brownlee M. Advanced protein glycosylation in diabetes and aging. Ann Rev Med 1995, 46:223-234.
10. Unoki H., Bujo H., Yamagishi S., Takeuchi M., Imaizumi T., Saito Y. Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes. Diabetes Res Clin Pract 2007, 76:236-244.
11. Unoki H., Yamagishi S. Advanced glycation end products and insulin resistance. Curr Pharm Des 2008, 14:987-989.
12. Veasey S. Obstructive sleep apnea: rapidly AGE-ing us all. Sleep 2006, 29:329-333.
13. Tasali E., Mokhlesi B., Van Cauter E. Obstructive sleep apnea and type 2 diabetes. Chest 2008, 133:496-506.
14. Tan K.C.B., Chow W.S., Lam J.C.M., Lam B., Bucala R., Betteridge J., et al. Advnaced glycation endproducts in non-diabetic patients with obstructive sleep apnea. Sleep 2006, 29:329-333.
15. Ip M.S.M., Lam B., Ng M.M.T., Lam W.K., Tsang K.W.T., Lam K.S.L. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002, 165:670-676.
16. Lam J.C.M., Lam B., Yao T.J., Lai A.Y., Ooi C.G., Tam S., et al. A randomized controlled trial of nasal continuous positive airway pressure on insulin sensitivity in obstructive sleep apnoea. Eur Respir J 2010, 35:138-145.
17. Lam J.C.M., Xu A., Tam S., Khong P.L., Yao T.J., Lam D.C., et al. Hypoadiponectinemia is related to sympathetic activation and severity of obstructive sleep apnea. Sleep 2008, 31:1721-1727.
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009;32(Suppl. 1):S62-7.
19. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. National Heart, lung, and blood institute joint national committee on prevention, detection, evaluation, and treatment of high blood pressure; national high blood pressure education program coordinating committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. Jama 2003, 289:2560-2572.
20. Kushida C.A., Littner M.R., Morgenthaler T., Alessi C.A., Bailey D., Coleman J., et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. SLEEP 2005, 28:499-521.
21. American Sleep Disorders Association. EEG arousals: scoring rules and examples: ASDA report. Sleep 1992;15:173-84.
22. Meoli L., Casey K.R., Clark R.W., Coleman J.A., Fayle R.W., Troell R.J. Hypopnea in sleep-disordered breathing in adults. Sleep 2001, 24:469-470.
23. Tan K.C., Chow W.S., Tam S., Bucala R., Betteridge J. Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 2004, 27:223-228.
24. Al-Abed Y., Bucala R. Structure of a synthetic glucose derived advanced glycation end-products that is immunologically cross-reactive with its naturally occurring counterparts. Bioconjug Chem 2000, 11:39-45.
25. Bonora E., Moghetti P., Zancanaro C., Cigolini M., Querena M., Cacciatori V., et al. Estimates of in vivo insulin action in man: comparison of insulin tolerance tests with euglycaemic, hyperglycaemic glucose clamp studies. J Clin Endocrinol Metab 1989, 68:374.
26. Hirst S., Philips D.I.W., Vines S.K., Clark P.M., Hales C.N. Reproducibility of the short insulin tolerance test. Diabet Med 1993, 10:839-842.
27. Tan K.C.B., Mackay I.R., Zimmet P.Z., Hawkins B.R., Lam K.S.L. Metabolic and immunologic features of Chinese patients with atypical diabetes mellitus. Diabetes Care 2000, 23:335-338.
28. Bucala R., Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992, 23:1-34.
29. Bohlender J.M., Franke S., Stein G., Wolf G. Advanced glycation end products and the kidney. Am J Renal Physiol 2005, 289:F645-F659.
30. Brownlee M., Cerami A., Vlassara H. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988, 318:1315-1321.
31. Akinmokun A., Selby P.L., Ramaiya K., Alberti K.G.M.M. The short insulin tolerance test for determination of insulin sensitivity: a comparison with the euglycemic clamp. Diabet Med 1992, 9:432-437.
32. Gelding S.V., Robinson S., Lowe S., Niththyananthan R., Johnson D.G. Validation at the low dose short insulin tolerance test for evaluation of insulin sensitivity. Clin Endocrinol 1994, 40:611-615.
33. Chen C.C., Wang T.Y., Hsu S.Y., Chen R.H., Chang C.T., Chen S.J. Is the short insulin tolerance test safe and reproducible?. Diabet Med 1998, 15:924-927.
34. Wallace T.M., Matthews D.R. The assessment of insulin resistance in man. Diabet Med 2002, 19:527-534.
35. Yamagishi S., Cai W., Altomonte J., Thung S.N. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications. Ther Apher Dial 2009, 13:534-539.
36. Hofmann S.M., Dong H.J., Li Z., Cai W., Altomonte J., Thung S.N., et al. Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 2002, 51:2082-2089.
37. Sano H., Higashi T., Matsumoto M., Melkko J., Jinnouchi Y., Ikeda K., et al. Insulin enhances macrophage scavenger receptor-mediated endocytic uptake of advanced glycation end products. J Biol Chem 1998, 273:8630-8637.
38. Dunaif A., Wu X., Lee A., Diamanti-Kandarakis E. Defects in insulin receptor signaling in vivo in the polycystic ovary syndrome (PCOS). Am J Physiol Endocrin Meta 2001, 281:392-399.
39. Miele C., Riboulet A., Maitan M.A., Oriente F., Romano C., Formisano P., et al. Human glycated albumin affects glucose metabolism in L6 skeletal muscle cells by impairing insulin-induced insulin receptor substrate (IRS) signaling through a protein kinase Cα-mediated mechanism. J Biol Chem 2003, 278:47376-47387.
40. Kaneto H., Fujii J., Myint T., Miyazawa N., Islam K.N., Kawasaki Y., et al. Reducing sugars trigger oxidative modification and apoptosis in pancreatic beta-cells by provoking oxidative stress through glycation reaction. Biochem J 1996, 320:855-863.
41. Unoki-Kubota H., Yamagishi S., Takeuchi M., Bujo H., Saito Y. Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin resistance in obese, type 2 diabetic mice. Protein Pept Lett 2010, 17:1177-1181.
42. Meerwaldt R., Links T., Zeebregts C., Tio R., Hillebrands J.-L., Smith A. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes-review. Cardiovasc Diabetol 2008, 7:1-8.
43. Tahara N, Yamagishi SI, Matsui T, Takeuchi M, Nitta Y, Kodama N, et al. Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in nondiabetic subjects. Cardiovasc Ther 2010. (Epub ahead of print).
44. Diamanti-Kandarakis E., Piperi C., Kalofoutis A., Creatsas G. Increased levels of serum advanced glycation end-products in women with polycytic ovary syndrome. Clin Endocrinol 2005, 62:37-43.
45. Diamanti-Kandarakis E., Katsikis I., Piperi C., Kandaraki E., Piouka A., Papavassiliou A.G., et al. Increased serum advanced glycation end-products is a distinct finding in lean women with polycytic ovary syndrome (PCOS). Clin Endocrinol 2008, 69:634-641.
46. Stirban A., Negrean M., Gotting C., Uribarri J., Gawlowski T., Stratmann B., et al. Dietary advanced glycation endproducts and oxidative stress: in vivo effects on endothelial function and adipokines. Ann NY Acad Sci 2008, 1126:276-279.